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"And the master-word is work . .. JJ
From the essay, "The Master-word in Medicine. JJ
-WILLIAM OSLER, 1903





A child falls and scrapes his knee. In a few days the injured
spot heals with a fresh layer of healthy skin, and the protective
barrier to environmental insults is restoted.
Another child, not so lucky, awakens every morning with
raw wounds on his cheeks caused by the pressure from his
pillow during the night. That boy, born with a single defective
gene that predisposes him to extensive blistering, is currently
a patient at The Rockefeller University Hospital. His condition,
like those of others for whom the skin's normal protective
functions have failed, is being studied and treated by researchers
of the laboratory for investigative dermatology, under the direc-
tion of Professor D. Martin Carter.
Dr. Carter came to Rockefeller from Yale University in 1981.
An innovator and ardent proselytizer in what until recently
has been an underpopulated and relatively unexplored science,
he has in four years established one of the most comprehensive
programs of dermatological research and treatment in the coun-
try, based at Rockefeller with associated services at New York
Hospital-Cornell Medical Center and Memorial Sloan-Kettering
Cancer Center.
The research in Dr. Carter's .laboratory has as its overall focus
a quest for deeper understanding of how the external environ-
ment interacts with genetic and other internal influences to
modulate the skin's responses. "We study these interactions,"
he says, "at the cellular level, the molecular level-the level D. Martin Carter
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of chromosomes and genes-and the biochemical level; in the
test tube and in the people we treat."
On the ward, he and his colleagues are applying new advances
in research, from his laboratory and others, to some old and
persistent problems that affect the skin: psoriasis, cancer, ulcer-
ation, epidermolysis bullosa (the boy's disease), Fanconi anemia,
pemphigus, aging.
, THE HAZARDS OF LIGHT AND AIR
The complexities of the skin's interactions with the environment
have been observed for a very long time. Thirty-five hundred
years ago people in India had discovered that extracts of certain
plants such as figs and wild parsnips, rubbed on the skin or
eaten, modifed the effects of vitiligo, a condition in which
large areas of the skin lack pigmentation. Scientists now know
that these plants are among a group that contains compounds
called psoralens, which react to light. At Yale, where he went
as a young dermatologist and subsequently earned a Ph. D. in
developmental biology, Dr. Carter participated in some of the
first studies of the mode of action of psoralens administered in
conjunction with ultraviolet irradiation. The technique, called
PUVA, is used in the treatment of psoriasis, a common and
sometimes serious skin disorder characterized by large, in'flamed
patches and heavy scaling.
A complicating side effect of PUVA, which the Yale study
determined and alerted the medical community to, is that it
can damage chromosomes. It can interfere with the activity of
DNA, the genetic material contained within the chromosomes
of cells, and increase the risk of skin cancer, just as can happen
with repeated, excessive exposure to sunlight. To minimize the
risk, Dr. Carter helped design psoralen blood-level tests in
order to limit irradiation to periods when the drug is most
accessible in skin cells.
Following those initial studies, Dr. Carter began to explore
the particular properties of psoralens as a tool for studying
basic cell behavior. In research that has continued at Rockefeller,
he and other members of his laboratory use PUVA to induce
damage to cells in culture in order to observe and characterize
the ways in which cells go about repairing themselves.
"We want to find out what kinds of repair mechanisms cells
have," he explains. "Are they more efficient at some times than
at others? Are some parts of DNA more protected or more
susceptible to injury? To help answer such questions, Peter
Ross, one of the colleagues who came to New York with me
from Yale, has been examining specific, defined pieces, or
sequences, of DNA, something we can do now that we know
how to clone genes. Our aim is to provide a critical test of
whether selective DNA repair in fact exists, and, if so, to
quantitate it. This kind of information should help us under-
stand more about processes like carcinogenesis."
Like sunlight, oxygen is an environmental agent vital to
life. But oxygen and the products of oxidation can damage
cells unless they are detoxified by protective mechanisms. Reac-
tive oxygen molecules are continually produced within cells
by respiration. Arthur Balin, who also first worked with Dr.
Carter at Yale, uses oxidative stress as a model system for
studying the process of aging, based on the theory th.at cellular
deterioration by oxygen is an underlying cause of aging.
'l\rthur and I got together through his interest in aging and
mine in DNA damage and repair," says Dr. Carter. "Since
coming to Rockefeller, weve been able to set up methods for
exploring the consequences of oxidative stress by growing skin
cells under various concentrations of oxygen. This hasn't really
been done before in a system~tic way."
"We're using human cells of all ages-the youngest from a
ten-week fetus and the oldest from a person over ninety---and
from normal subjects and patients with inherited defects of
DNA stability," Dr. Balin says. 'l\nd we've been discovering
some interesting things. For example, weve found that
physiologic levels of oxygen regulate both the growth and the
lifespan of human cells. We've also learned that different kinds
of cells in the skin respond differently to different oxygen levels;
they have different optimal growth requirements. What we
normally think of as a bland environment-air with twenty
percent oxygen concentration-is highly toxic to cells growing
singly or in low densities. If you reduce the oxygen concentra-
tion, they grow better and their lifespan can be extended."




of causes, such as varicose veins or diabetes, or follow surgery
or severe injury, affecting younger people as well. Relentless
leg ulcers sometimes accompany sickle cell disease. Because of
the trials we run, we get to see the very worst cases.
"Healing is influenced by a number of factors. Age is an
important one, since old people heal more slowly than the
young. The acid level in a wound area will affect the growth
of infectious bacteria. The degree of moisture will influence
the growth of new cells, but exactly how has been a subject
of continuing debate. At one time, so little was understood
about the effects of moisture that doctors used to joke, if the
skin is wet, dry it, if it's dry, wet it, and if nothing works,
put the patient in a tub of oatmeal. Our tests and others have
shown clearly that healing is accelerated in a moist environment
in which cells can move about freely."
Dr. Carter and his group test various medications and wound
dressings currently in use or being developed, frequently at
the request of the companies that make the products. They are
applying Dr. Balin's findings, reducing oxygen concentrations
around wounds to speed cell growth. They also are using cell
technology to help develop new kinds of dressings.
One kind of dressing scientists find particularly promising,
for both wounds and burns, is made from skin itself. The major
obstacle in skin grafting from ~ donor is rejection by the im-
munological system. To eliminate the problem, some research-
ers, Dr. Carter among them, are experimenting with grafts
made from the patient's own skin. A problem here is that if a
large piece is needed, there is a risk that the graft may create
a troublesome wound or disfiguring scarring. To get around
this, Dr. Carter has adapted a technique introduced by Mag-
dalena Eisinger of Memorial Sloan-Kettering and Jack Hefton
of Cornell, in which skin is grown in culture from small starter
grafts.
As he explains: "We've developed a device that raises a suction
blister, a relatively painless and noninvasive procedure. In the
blister, the epidermis, the outer layer of the skin, separates
from the dermis. You can then cut off the top--the epidermis-
and in two or three weeks, from a piece of tissue the size of a










One of Dr. Carter's priorities when he came to New York was
to set up clinical and experimental facilities for studying and
improving the process of wound healing. The wounds his lab-
oratory is concerned with are chronic and intractable.
"Leg ulcers plague the elderly, many of whom spend months
bedridden in hospitals," he says. "They can result from a variety
d _
a way to learn more about fundamental factors in aging. At
the same time," Dr. Carter points out, "we're putting the
information about optimal conditions for cell growth to work
clinically in the- treatment of wounds."
FAT CELLS
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Photomicrograph of a section of
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this cellophane-thin epidermal membrane over the wound, and
when the cells take up residence supporting skin cells begin
to attach themselves underneath. It's been our experience that
wounds healed this way tend not to reopen."
During the past three years, the laboratory has used the
method successfully with a large number of patients whose
wounds have failed to respond to any other approach. One
current patient, so far responding well, is a forty-seven-year-old
man crippled with arthritis, whose leg ulcers have delayed for
four years the hip replacement surgery that will make it possible
for him to walk again. Another is the boy with epidermolysis
bullosa, or EB.
WHEN GENES GO WRONG
"It's a dreadful disease," says Dr. Carter. "A little irritation that
you or I would hardly notice can produce extreme blistering
in someone with EB. There are up~ards of twenty forms of
the disease, classified genetically according to where the blisters
appear in the skin. The amount of scarring incurred depends
on the depth of the blisters. The mild forms are, at best,
aggravating nuisances. For people with severe forms, it's like
being constantly burned from the day yoille born. They're prone
to massive infections and to cancer from the recurrent irrita-
tions. Their muscles atrophy, the mucous membranes in their
respiratory and gastrointestinal tracts are often damaged so they
have trouble breathing and eating, and their vision can be
impaired. In the recessive dystrophic form, where the blisters-
the bullae-go down into the dermis, the fingers and toes
fuse, encased in scar mittens."
There is no cure for EB and the underlying mechanisms are
still not understood. Current research implicates a malfunction-
ing of collagenase, an enzyme that breaks down collagen, the
jellylike protein substance that comprises the major material
of connective tissue and bone. As a result of the enzyme's defect,
the epidermis doesn't anchor properly to the dermis in some
types of EB.
EB is an "orphan" disease, a term used to denote conditions,
usually rare ones, rhat don't get much attention or research
money. Recently, the government passed an Orphan Drug Act
to fund some trials, including a trial of the drug phenytoin
(Dilantin) as a treatment for EB. First developed for epilepsy,
phenytoin seems to inhibit collagenase activity. Dr. Carter is
heading the project, which is being conducted at Rockefeller
and seventeen other medical centers.
Fanconi anemia is another rare, inherited disease that affects
the skin, as well as the blood, the kidneys, and the bones. FA
victims suffer bone marrow failure, anemia, infection, hemor-
rhage, leukemia, and squamous cell cancer. They rarely live to
adulthood.
While a postdoctoral fellow at Memorial Sloan-Kettering,
Arleen Auerbach developed prenatal and postnatal diagnostic
tests for Fanconi anemia. She studied cells from patients and
from carriers of the genetic trait to determine their varying
degrees of sensitivity to agents that can induce mutations or
cancer. Her work contributed to a procedure that reduced the
toxicity of bone marrow transplants, an important treatment
for the disease. Since joining Dr. Carter's laboratory in 1982,
she has developed a method for prenatal diagnosis i~ the first
trimester of pregnancy. She is now studying the genetic
heterogeneity of the disease with the goal ofeventually mapping
and isolating the gene responsible. Two years ago, in collabora-
tion with Dr. Traute Schroeder of the University of Heidelberg,
she established an International Fanconi Anemia Registry to
gather patient histories including genetic, cellular, and clinical
data, and information on the role of environment in the onset
of the disease. She also provides prenatal counseling for FA
families.
Because diseases that affect the skin can result from different
underlying causes and involve different mechanisms, the scien-
tists who work with Dr. Carter come from many fields, their
arrival in dermatological investigations often serendipitous. Dr.
Balin holds an M.D. and a Ph.D. in biochemistry from the
University of Pennsylvania and Dr. Ross a Ph. D. in molecular
genetics from Yale. Among the dermatologists based primarily
at New York Hospital, Steven Cohen, a former olympic gym-
nast, is a specialist in occupational health, Scott McNutt is a
pathologist, Philip Prioleau is a surgeon, and Rachelle Scott
is a pediatrician whose interest in dermatOlogy developed from
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Peter Ross, left, and Postdoctoral
Associate Noboru Matsuo in the
laboratory where DNA is isolated
to learn about how cells repair
themselves.
her work with a Harlem community health project.
"Inherent in any research," Dr. Carter assertS, "is the possi-
bility-the likelihood--{)f uncovering information with impli-
cations that cross disciplinary boundaries." Zofia Borowska,
who has been at Rockefeller for twenty-four years, the last four
with Dr. Carter, is a biochemical geneticist who began her
career in the laboratory of the late Nobel prizewinning geneticist
Edward Tatum. She has conducted a range of investigations
stemming primarily from her findings concerning the action
of antibiotics on cellular proteins. Most recently, with Dr.
Auerbach, she has been applying her knowledge qf protein
function to the study of Fanconi anemia. This summer she
moved from the study of genetic disease to the laboratory of
Professor David Mauzerall, who studies photosynthesis and
photobiological evolution. "It's not such a strange switch," she
explains. "It's all biochemically related."
Alice Gottlieb is an immunologist with an M.D. from Cor-
nell and a Ph.D. from Rockefeller. She was trained in the
laboratory of the late Henry G. Kunkel, who led seminal
research in autoimmunity, a process in which the body's immune
defense system turns on the body itself. Her initial interest
was lupus, one of the autoimmune diseases with skin manifes-
tations. Now with Dr. Carter's group, she is studying certain
antibodies that have affinities for specific areas of the skin.
(Antibodies are the chemical bullets the immune system fires
at molecules it perceives as foreign invaders--{)r misperceives,
in autoimmune disease.) She has been developing a battery of
monoclonal antibody probes that are helping to characterize
the ways in which skin cells respond to various diseases.
James Krueger, another Rockefeller-Cornell M.D.-Ph.D.
graduate, started out in virology. He recently finished medical
school and is studying pemphigus, also an autoimmune disease.
"Before steroid and immunosuppressant therapy," says Dr. Car-
ter, "pemphigus victims uniformly died of its effects. Now
they sometimes die from the treatment. Jim is interested in
defining the immunologic aberrations expressed in pemphigus,
and together he and I have started looking at it as a general
model for autoimmune diseases of the skin."
ROOTS AND TENDRILS
Martin Carter had intended a career as a "regular" doctor. There
have been physicians in his family for more than a century,
mostly in Missouri, where he grew up in the small river town
of Doniphan. His entry into research was, he says, a consequence
of the Cuban missile crisis.
"I was interning at the time at the University of Rochester
and, being newly married, I decided to join the medical officer
deferment program of the Public Health Service. I had some
background in infectious diseases so I thought maybe theya
send me to Tahiti or someplace like that. They sent me to
Philadelphia-with instructions to wipe out syphilis. I didn't
quite manage to do that, but I did get to meet a lot of people
from the groups that work at Philadelphia General Hospital.
One of them was George Hambrick from the University of
Pennsylvania, which was then one of the few places where
dermatological research was going on. As I got to know George,
I realized that dermatology interested me much more than
internal medicine."
With Dr. Hambrick's encouragement, Dr. Carter applied
and was accepted for a residency in dermatology at the Univer-
sity of Pennsylvania, and from there went to Yale, where in
1970 he became the first Howard Hughes Investigator in der-
matology, and where he remained for fourteen years until the
invitation came from Rockefeller.
"Moving to New York was a difficult decision," he says. "I
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had a very good group in New Haven and we have a lovely,
old house in the Connecticut countryside that my family and
I get co go to now only on occasional weekends and holidays.
But I couldn't resist the opportunity to put together the kind
of program I knew could be achieved with the extraordinary
resources in and around Rockefeller." One of his first acts on
accepting the post was to coax Dr. Hambrick out of semiretire-
ment to become co-chief with him of the dermatology division
at Cornell Medical Center.
In their days at the University of Pennsylvania, George Ham-
brick remembers urging Dr. Carter to become "more than JUSt
a clinician." Beyond an obvious talent for research, Dr. Ham-
brick saw in his young colleague "a born organizer. Marty's a
builder, a communicator. Dermatology has suffered from an
image problem. People go to dermatologists looking for an
easy solution, a quick fix. But solutions don't come without
study, and there hasn't been enough in dermatology. Marty has
done a lot to raise the level of the science and the image."
If Dr. Carter became more than just a clinician, he has
nonetheless remained very much a hands-on doctor, as he de-
scribes himself, deeply involved in the day to day care of his
patients as well as in the training of a growing number of
young cutaneous biologists. Like him, these new clinical resear-
chers spend their days shuttling between the laboratory and
the clinic. "The questions I'm interested in answering as a
scientist," he says, "arise from the clinical setting. I don't think
10 know what questions to ask without patients."
When patients come to Dr. Carter's clinic at Rockefeller, it's
likely the first person they meet will be Dorothea Caldwell.
Often, she's the reason they've come in the first place. The boy
receiving skin grafts is from Texas. The wounds that are now
healing had been reopening for three years. His mother learned
about Dr. Carter's work at a meeting of EB parents at which
Dorothea Caldwell spoke. A nurse-practitioner with thirteen
years of experience and a master's degree in public health, Ms.
Caldwell is the clinical coordinator for the laboratory and, as
such, bears the major responsibility for enlisting and screening
patients, supervising their care in coordination with the labo-
ratory's physicians, and contributing to the research protocols.
"I wasn't sure I'd be interested in dermatology," she says,
"but now I don't think I could ever leave. You get so involved
with these patients. We usually have about eight inpatients at
anyone time, and we follow about a hundred outpatients,
including some thirty EB families. With EB you find yourself
nursing whole. families because it's the kind of disease that
devastates every member. We try to get to them as early as
possible. We have a referral pattern established so that doctors
transfer babies from the newborn nurseries directly to us. The
younger we begin treatment the better chance we have of pre-
venting the worst effects. Until now, most of these people didn't
know where to turn, and .there was so little to offer them in
the way of help...
The Carter family has put down roots in New York, literally
and figuratively. Mrs. Carter, a writer who unwinds by garden-
ing, does her digging these days in Central Park. "She's one
of the worker bees there," says her husband, "planting bulbs
and hoeing. Our kids-we have three, all grown-think it's
very funny when they see her running around picking up litter."
Dr. Carter, a passionate music lover, sings with the St. Andrew's
Chorale of the Madison Avenue Presbyterian Church, and, ac-
cording to Dorothea Caldwell, "if you're nOt an opera buff when
you come to this lab you soon become one."
"I figured," Martin Carter says, "if I was going to start
something new somewhere 10 rather do it here than anywhere
else. For clinical research, Rockefeller is the premier place." 0
